The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Official Title: Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Study ID: NCT05744687
Brief Summary: This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Fujian Cancer Hospital, Fuzhou, Fujian, China
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
AnYang Tumor Hospital, Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Renmin Hospital of Wuhan University Hubei General Hospital, Wuhan, Hubei, China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Pingxiang People's Hospital, Pingxiang, Jiangxi, China
The Second Norman Bethune Hospital of Jilin Univer, Chang chun, Jilin, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Tai'an Central Hospital, Tai'an, Shandong, China
Peking University Cancer Hospital, Beijing, , China
Tianjin Medical University cancer Institute & Hospital, Tianjin, , China